Mometasone Furoate topical

Synthetic nonfluorinated corticosteroid.1 2 3 6 10

Corticosteroid-responsive Dermatoses

Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.1 2 3 7 10 a

Generally most effective in acute or chronic dermatoses (e.g., seborrheic or atopic dermatitis, localized neurodermatitis, anogenital pruritus, psoriasis, late phase of allergic contact dermatitis, inflammatory phase of xerosis).d

Topical therapy generally preferred over systemic therapy; fewer associated adverse systemic effects.d

Topical therapy generally only controls manifestations of dermatoses; eliminate cause if possible.d

Topical efficacy may be increased by using a higher concentration or occlusive dressing therapy.d (See Administration with Occlusive Dressing under Dosage and Administration.)

Response may vary from one topical corticosteroid preparation to another.d

Anti-inflammatory activity may vary considerably depending on the vehicle, drug concentration, site of application, disease, and individual patient.d

Should not be used in the treatment of acne, rosacea, or perioral dermatitis.8

Specific Drugs and Laboratory Tests

• Medium-range corticosteroid activity.a b c d

• Produces anti-inflammatory, antipruritic, and vasoconstrictive actions,a b c possibly resulting in part from steroid receptor binding.d

• Anti-inflammatory effects may occur through induction of phospholipase A2 inhibitory proteins (lipocortins), which are thought to inhibit release of arachidonic acid from membrane phospholipids, thereby downregulating biosynthesis of potent inflammatory mediators (e.g., prostaglandins, leukotrienes).a b c

• Importance of using only as directed, only for the disorder for which it was prescribed, and for no longer than prescribed; avoid contact with the eyes and only apply externally as directed.a b c (See Topical Administration under Dosage and Administration.)

• Importance of discontinuing therapy when control is achieved.a b c Consult clinician if no improvement is noted after 2 weeks.a b c

• Importance of informing patients that treated areas of the skin should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by a clinician.1 2 9 10 a

• Importance of not applying to the face, underarms, or groin areas unless directed by the clinician.a b c

• Importance of reporting any local adverse reactions, especially those occurring under occlusive bandage, to clinician.a b c

• Importance of informing parents of children receiving the drug that if mometasone is applied in the diaper area,a b c tight-fitting diapers or plastic pantsd should not be used since they may act as an occlusive dressing.a b c d

• Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs; other corticosteroid-containing preparations should not be used without first consulting with clinician.a b c

• Importance of women informing clinician if they are or plan to become pregnant or plan to breast-feed.a b c

• Importance of informing patients of other important precautionary information.a b c (See Cautions.)